Compass Rose Asset Management LP Has $408,000 Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

Compass Rose Asset Management LP lifted its position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 150.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 250,000 shares of the company's stock after buying an additional 150,000 shares during the quarter. Sana Biotechnology comprises approximately 0.2% of Compass Rose Asset Management LP's holdings, making the stock its 14th biggest position. Compass Rose Asset Management LP owned approximately 0.11% of Sana Biotechnology worth $408,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in SANA. Cerity Partners LLC acquired a new stake in Sana Biotechnology during the 4th quarter valued at $25,000. Tower Research Capital LLC TRC lifted its holdings in Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares during the last quarter. Syon Capital LLC acquired a new stake in Sana Biotechnology during the 4th quarter valued at $27,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the third quarter worth $29,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth $29,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA traded up $0.31 during mid-day trading on Monday, reaching $2.13. The company had a trading volume of 4,595,924 shares, compared to its average volume of 3,315,490. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $9.49. The firm has a market cap of $479.14 million, a price-to-earnings ratio of -1.52 and a beta of 1.75. The business's 50-day simple moving average is $1.93 and its 200 day simple moving average is $2.47.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. On average, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

SANA has been the subject of a number of research reports. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Tuesday, March 18th. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Jefferies Financial Group initiated coverage on Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.